Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, medical devices, and a wide array of sensors. We believe that Masimo SET® helps clinicians monitor in excess of approximately 100 million patients in healthcare settings around the world,1 and is the primary pulse oximetry technology at 17 of the top 20 hospitals listed in the 2017-2018 U.S. News & World Report Best Hospitals Honor Roll.2
Joe Kiani founded Masimo in 1989 as a private "garage start-up" company because he was convinced that the use of adaptive signal processing in the measurement of physiological parameters could solve the problems of low perfusion and motion, which had long plagued in-vivo monitoring and especially pulse oximetry, the measurement of the oxygen saturation of arterial blood. His solution, Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, was shown in a study comparing three pulse oximetry technologies to demonstrate the highest sensitivity and specificity in identifying desaturation events during conditions of motion and low perfusion.3
Today, Masimo is publicly traded and employs over 4,600 people worldwide, with annual revenues of approximately $800 million. Licensing agreements allow Masimo technology to work inside monitoring devices from a host of manufacturers, including Philips, Atom, Mindray North America, GE Medical, Medtronic, Spacelabs, and Zoll. Throughout its more than 25-year journey, Masimo’s mission – to improve patient outcomes and reduce the cost of care – has remained strong.
rainbow®, introduced in 2005, allows additional parameters to be noninvasively and continuously monitored. Advanced signal processing algorithms and unique adaptive filters work together to isolate, identify, and quantify various types of hemoglobin.
Masimo SET® and rainbow® technologies, collectively known as rainbow SET™, fuel medical monitoring devices such as Root®, Radical-7®, Radius-7®, Rad-97™, and Rad-57® as well as a multitude of sensors, including the RD collection. These highly-versatile monitors are configurable for use in a variety of high- and low-acuity hospital settings, from ICUs and surgical suites to post-operative floors, as well as in long-term care facilities and in the case of Rad-97, for home use.
Complementing devices that primarily monitor continuously, Masimo spot-check devices such as Pronto® and MightySat™ Rx allow physician offices, EMS responders, and others to measure oxygen saturation and other valuable measurements. MightySat, alongside the smart device-enabled iSpO2®, is also available for personal use for general health and wellness applications.
Masimo continues to expand what can be monitored and how. Root, for example, was built from the ground up to be as flexible and expandable as possible, with Iris™ ports and Masimo Open Connect® (MOC-9®) to facilitate the addition of other Masimo and third-party monitoring technologies. Key Masimo additions include:
SedLine helps clinicians monitor the state of the brain under anesthesia with bilateral data acquisition and processing of four leads of electroencephalogram (EEG) signals. Next Generation SedLine features an enhanced signal processing engine, driving a variety of performance improvements such as an enhanced Density Spectral Array (an easy-to-interpret, high-resolution display of bi-hemispheric activity and EEG power) and an improved Patient State Index (PSi; a processed EEG parameter related to the effect of anesthetic agents).
O3 may help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain.
Integrated NIBPT measurements automate vital sign documentation in hospital EMRs. Rad-97 is similarly available in a configuration with integrated NIBP.
ISA™ capnography for sidestream CO2 and gas monitoring features NomoLine™ technology for extended monitoring and cost-effective consumables. Rad-97 is available in a configuration with integrated NomoLine CO2 capnography.
Joining the expanding set of monitoring possibilities are redefined and extended connectivity and automation. Masimo Iris Gateway™ gathers medical data from devices throughout the hospital, including ADT, and converting and transferring them to a central repository, the EMR, thus automating clinician access to a more complete picture of each patient. To those abilities, Masimo Patient SafetyNet™* with Replica™ adds hospital-wide monitoring and two-way remote clinician notification from a central server and customizable view stations, and mobile devices. The wearable Masimo Radius-7 allows for the tetherless monitoring of mobile patients, communicating alarms wirelessly back to Root and Patient SafetyNet.
*The use of the trademark Patient SafetyNet is under license from University Health System Consortium.
Estimate: Masimo data on file.
Shah N et al. J Clin Anesth. 2012 Aug;24(5):385-91.
Rad-97 with NomoLine Capnography is not licensed for sale in Canada.
Irvine, CA 92618
© 2018 Masimo. All Rights Reserved.